메뉴 건너뛰기
New England Journal of Medicine
Volumn 371, Issue 16, 2014, Pages 1556-1557
Lanreotide in metastatic enteropancreatic neuroendocrine tumors
Author keywords

[No Author keywords available]
Indexed keywords

ANGIOPEPTIN; GALLIUM 68; KI 67 ANTIGEN; MEMBRANE RECEPTOR; PENTETREOTIDE; PROTEIN SSTR; SOMATOSTATIN RECEPTOR; TRACER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; DRUG DERIVATIVE; SOMATOSTATIN;
EID: 84908072538     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1409757     Document Type: Letter
Times cited : (428)
References (5)
  • 1
    • 84874875874 scopus 로고    scopus 로고
    • Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors
    • Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2013; 54:364-72.
    • (2013) J Nucl Med , vol.54 , pp. 364-372
    • Wild, D.1    Bomanji, J.B.2    Benkert, P.3
  • 2
    • 84872054168 scopus 로고    scopus 로고
    • Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors
    • Palazzo M, Lombard-Bohas C, Cadiot G, et al. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. Eur J Gastroenterol Hepatol 2013;25:232-8.
    • (2013) Eur J Gastroenterol Hepatol , vol.25 , pp. 232-238
    • Palazzo, M.1    Lombard-Bohas, C.2    Cadiot, G.3
  • 3
    • 84890280115 scopus 로고    scopus 로고
    • Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: Implications for dose optimization
    • Heidari P, Wehrenberg-Klee E, Habibollahi P, Yokell D, Kulke M, Mahmood U. Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization. Cancer Res 2013;73:6865-73.
    • (2013) Cancer Res , vol.73 , pp. 6865-6873
    • Heidari, P.1    Wehrenberg-Klee, E.2    Habibollahi, P.3    Yokell, D.4    Kulke, M.5    Mahmood, U.6
  • 4
    • 35348933794 scopus 로고    scopus 로고
    • Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: A proposal of scoring system correlated with somatostatin receptor scintigraphy
    • Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007;20:1172-82.
    • (2007) Mod Pathol , vol.20 , pp. 1172-1182
    • Volante, M.1    Brizzi, M.P.2    Faggiano, A.3
  • 5
    • 33751001270 scopus 로고    scopus 로고
    • Rationale for the use of somatostatin analogs as antitumor agents
    • Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17:1733-42.
    • (2006) Ann Oncol , vol.17 , pp. 1733-1742
    • Susini, C.1    Buscail, L.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.